Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.…
What Makes Keros Therapeutics (KROS) a New Strong Buy Stock
Keros Therapeutics (NASDAQ: KROS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 87 employees.
The shares were at 11.08 USD on 20 November 2026, down 31.6% over 52 weeks. Its 52-week range is 8.980 USD to 22.55 USD: the price is 50.9% below the high and 23.4% above the low.
Its market capitalisation is 217.44M USD.
Keros Therapeutics reports return on equity of 28.7%, an operating margin of -172.4% and revenue up 180.5% year over year.
It holds more cash than debt, a net cash position of 244.35M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 20.00 USD is 80.5% above the current price. The next earnings report is expected on 3 March 2027.